Background: Oral immunotherapy (OIT) successfully desensitizes patients with food
| INTRODUCTION
Food allergy is a major public health problem that is estimated to affect 6%-8% of all children and up to 3% of adults in developed countries. 1, 2 Moreover, the prevalence of peanut allergy has markedly increased in the past decade for reasons that are unclear. 3 The current standard of care for food allergy is to avoid the offending foods and to pharmacologically treat food allergic reactions when they occur.
Oral immunotherapy (OIT) is currently being investigated as treatment modality to modify disease outcome by inducing unresponsiveness to food allergens. 4 OIT has been proven efficacious in desensitizing the majority of subjects with food allergy to their offending allergen, achieving 50%-80% response rates. 5 However, induction of sustained unresponsiveness following cessation of OIT has remained problematic. For example, while up to half of the subjects with peanut allergy remain unresponsive to peanut challenge 1 month following cessation of OIT, 6 only 13% remained unresponsive 6 months following cessation of therapy. 7 The mechanism(s) by which OIT mediates allergen desensitization remain to be fully elucidated. 8 Of particular interest is the role in the process of FOXP3 + regulatory T (Treg) cells, given their cardinal function in actively maintaining oral tolerance in the gut. 9 , 10 Jones and co-workers found that the number of FOXP3 + T cells observed in cultures of peripheral blood cells stimulated with peanut increased until 12 months of OIT and then decreased afterwards. 11 Earlier studies showed that the ratio of FOXP3 high to FOXP3 intermediate reg-
ulatory T cells (Treg cells) stimulated with peanut increased 1 year
into peanut OIT. 12 More recently, Syed et al 7 found that patients who were "immune tolerant" to peanut, or were able to pass an oral food challenge after interrupting OIT for 3-6 months, had higher numbers of allergen-induced Treg cells with greater suppressive function and with higher levels of FOXP3 hypomethylation, compared to non-tolerant subjects. Increased allergen-responsive Treg cells have also been noted upon naturally occurring tolerance acquisition to food in allergic subjects, indicative of common mechanisms operative in both natural and OIT-induced oral tolerance acquisition. [13] [14] [15] A critical observation explaining the failure of food allergen-specific Treg cells to control disease is the acquisition by these cells of Th2 cell-like phenotype with increased IL-4 production, imparting a Th2 cell-like phenotype, which impairs their regulatory function. 16, 17 The capacity of OIT to reverse this aberrant programme is unknown.
We have developed an OIT protocol combined with the anti-IgE monoclonal antibody therapy omalizumab (Xolair, Genentech) that increased the rapidity of food allergy desensitization. [18] [19] [20] In patients who were desensitized to milk after receiving omalizumab, there was an acute and significant reduction in milk-specific T cell responses, without increased FOXP3 + Treg cell development, suggesting the induction of anergy or deletion of T effector (Teff) cells. 21 The initially reduced Teff cell response was later replaced by a CD4 + T cell response characterized by reduced IL-4 production, accompanied by decreased milk-specific IgE responses, attenuated milk-specific basophil degranulation and increased milk-specific serum IgG4 concentrations. 21 Here, we investigated the immunological mechanisms by which OIT supplemented by omalizumab mediates clinical improvement.
We describe the dynamic peanut-specific immunological changes in a pilot cohort of children who received open-label peanut OIT with omalizumab. 19 We show that OIT supplemented with omalizumab suppressed the Th2 cell-like phenotype of peanut-specific Treg cells and restored their function, an effect that could be recapitulated in vitro by the blockade of IL-4R signalling in Treg cells. Our findings support a major role for the functional restoration of allergen-specific Treg cells in mediating long-term beneficial effects of omalizumab/OIT therapy. They also provide mechanistic insights into how such an effect is achieved, which can be harnessed to further improve the efficacy of future OIT protocols.
| METHODS

| Study population
We evaluated blood samples from 13 peanut-allergic patients (8 boys and 5 girls) originally reported by Schneider et al 19 who underwent OIT supplemented by omalizumab. All patients had a history of significant IgE-mediated peanut allergy (defined as having a significant immediate reaction with peanut ingestion, including generalized urticaria, vomiting and/or anaphylaxis). 19 These patients failed an initial double-blind placebo-controlled food challenge (DBPCFC) at peanut protein doses of 50 mg or less. At enrolment, the median age was 10 years, the median peanut-specific IgE level was 229 kU/L, and the median total serum IgE level was 621 kU/L. The peanutspecific allergic responses in the course of the study are detailed in Table S1 . An additional 5 untreated children who met clinical and laboratory criteria for IgE-mediated peanut allergy were recruited for studies on the impact of IL-4R neutralization on peanut-specific Treg cell function (Table S2 ). The Institutional Review Board of Boston Children's Hospital approved the protocol, and all participants and/or their parents provided written informed consent. This study was registered on ClinicalTrials.gov (NCT01290913). 
| Proliferative labelling and cell culture
| RESULTS
| Patient OIT and clinical outcomes
Patient demographics, omalizumab-enabled OIT protocol and clinical outcomes at 1-year post-initiation of OIT have been previously reported. 19 Details of clinical outcomes between weeks 52 and 104
are described in Table S1 . Of the 13 initially enrolled subjects, 2 dropped out of the study at weeks 16 (patient 04) and 45 (patient 07), and a third subject dropped out at week 90 (patient 08), all due to OIT-related side effects.
| Peanut-specific CD4 T cell proliferation is reduced during rush desensitization
PBMC were isolated at multiple time-points during the desensitization protocol ( Figure S1 ) and frozen in aliquots in liquid nitrogen for later CD28 mAb beads (D and E). Graph represents average data for all patients normalized to day 0 AE SEM over the course of the study. ****P < .0001 versus baseline determined using paired t-test. F-I, Representative plots at 4 weeks 0, 12, 52, and 104 of % peanut-specific Violet low CD4 + CD3 + FOXP3 + cells. G and I, Graphs representing the average data for all patients normalized to day 0 AE SEM over the course of the study. *P < .05, **P < .01, ****P < .0001 by 1-way ANOVA with post-test analysis with comparisons made to week 12 values ( Figure 1C) , although for most patients they did not reach their pretreatment levels. These changes in peanut-stimulated proliferative responses were specific in that they were not observed with the anti-CD3 mAb treatment or upon stimulation with tetanus toxoid ( Figure 1D ,E, Figure S3A We also analysed the peanut-specific T cell proliferative responses in the 3 patients who did not respond to OIT treatment.
Although there was an initial drop in the number of peanut-specific Food allergy is associated with the acquisition of food allergen-specific Treg cells of a Th2 cell-like phenotype that contributes to disease pathogenesis. 16, 17, 23 In agreement with our findings in the murine model and in human subjects with milk allergy, 17 the peanut-allergic patients in our study had a high frequency of peanut-specific proliferat- Figure 3A , and a scheme illustrating the CD45RA/CCR7 marker combinations of the different memory subsets is shown in Figure 3B . The distribution of memory subsets among Violet 
| DISCUSSION
In this study, we investigated the immune mechanisms of OIT in a cohort of 13 high-risk peanut-allergic children who underwent a rapid high-dose oral desensitization protocol facilitated with omalizumab. 19 The cell suppressive function of allergen-specific Treg cells, measured at 1 year after the initiation of therapy, was markedly augmented in patients who were successfully desensitized to Results shown in panels B, E and F represent means AE SEM of data derived from cultures of 5 peanut-allergic subjects. *P < .05, **P < .01, ***P < .001 by paired 1-way ANOVA with post-test analysis allergic subjects may reflect in part augmented immunological suppression mediated by Treg cells.
We have previously shown that food allergy is associated with the acquisition of allergen-specific Treg cells of a Th2 cell-like phenotype with IL-4 production that contributes to disease pathogenesis. 17 In this study, we also found that peanut-reactive Thus, the 2 approaches appear to be synergistic in inducing desensitization, although more rigorous studies using peanut versus placebo-controlled groups would be required to make this distinction.
Both Treg-dependent and Treg-independent mechanisms have been previously been invoked in the induction of tolerance upon oral immunotherapy. In a recent study by Frischmeyer-Guerrerio et al 35 ,
the addition of omalizumab to OIT in milk allergy did not alter the frequency of casein-specific Treg cells. However, the functional responses of milk-specific Treg and Teff cell responses were not reported in this study. 35 Other proposed mechanisms include anergy and/or deletion of allergen-specific Treg cells. 21, 36 In our study, the in vitro addition of IL-2 failed to rescue the decreased proliferation of peanut-specific CD4 + Teff or Treg cells, suggesting that anergy was not a major mechanism for the observed decline in peanut reactivity. Also, neutralization of IL-10 failed to alter peanut-specific T cell responses. We cannot, however, rule out deletion of peanut-specific T cells as a mechanism by which suppression of peanut reactivity may be occurring in parallel with the enhanced Treg cell-induced suppression. 21, 37 Future studies aiming to determine the frequency of allergen-specific T cells by staining with peanut peptide-presenting recombinant tetrameric complexes of HLA-DR molecules coupled with T cell receptor-sequencing approaches would enable determination of the role of T cell clonal deletion in long-term oral tolerance induced by OIT. 
